Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr99.50 DKK
Change Today -5.00 / -4.78%
Volume 214.8K
ZEAL On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
OTC US
As of 11:04 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Open
kr104.00
Previous Close
kr104.50
Day High
kr104.00
Day Low
kr98.50
52 Week High
03/23/15 - kr122.00
52 Week Low
10/16/14 - kr58.00
Market Cap
2.3B
Average Volume 10 Days
103.1K
EPS TTM
kr-2.87
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, discovers and develops peptide drugs in Denmark. Its lead drug includes Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company’s product pipeline also comprise Lantus and Lyxumia, which are in Phase III clinical trials for the treatment of type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist that is in Phase I clinical trial for the treatment of diabetes and/or obesity. In addition, it develops danegaptide, a dipeptide gap junction modifier in Phase II clinical study with cardioprotective properties; ZP1480, an MSH melanocortin peptide agonist in Phase IIb clinical trial for the prevention of acute kidney injury following surgery; Elsiglutide, a GLP-2 peptide receptor agonist in Phase II clinical trial for the prevention of chemotherapy induced diarrhea; and ZP1848, a GLP-2 peptide agonist that has completed Phase Ib trial for the treatment of inflammatory bowel disease. Further, the company has peptide drug programs in various stages of pre-clinical development, primarily in the fields of cardio-metabolic diseases, diabetes, and obesity. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; Abbvie Inc.; and Eli Lilly. The company was founded in 1998 and is based in Copenhagen, Denmark.

103 Employees
Last Reported Date: 03/13/15
Founded in 1998

zealand pharma a/s (ZEAL) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S, Board Meeting, Apr 11, 2015

Zealand Pharma A/S, Board Meeting, Apr 11, 2015.

Zealand Pharma A/S, Board Meeting, Mar 25, 2015

Zealand Pharma A/S, Board Meeting, Mar 25, 2015. Agenda: To adopt new provisions in accordance with Article 8.1 of the Articles of Association concerning the issuing of warrants to certain employees of the company.

Zealand Pharma A/S, Board Meeting, Nov 19, 2012

Zealand Pharma A/S, Board Meeting, Nov 19, 2012. Agenda: To resolve to issue warrants (2012-2 employee incentive program) corresponding to a nominal amount of DKK 214,883 shares; and to resolve to increase the share capital of the company in accordance therewith.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr99.50 DKK -5.00

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.8x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.